Chronic myelogenous leukemia is a malignant disease of the hematopoietic stem cell compartment, which is characterized by expression of the BCR-ABL fusion protein. Expression of BCR-ABL allows myeloid cells to grow in the absence of the growth factors interleukin-3 and granulocyte-macrophage colony-stimulating factor. The tyrosine kinase activity of BCR-ABL constitutively activates signaling pathways associated with Ras and its downstream effectors and with the Jak/STAT pathway. Additionally, we reported previously that BCR-ABL activates the transcription factor nuclear factor-KB (NF-KB) in a manner dependent on Ras and that inhibition of NF-KB by expression of a modified form of IKBA blocked BCR-ABL-driven tumor growth in a xenograft model. Here, we show that a highly specific inhibitor of IKB kinase B, a key upstream regulator of the NF-KB pathway, induces growth suppression and death in cells expressing wild-type, Imatinib-resistant, or the T315I Imatinib/Dasatinibresistant forms of BCR-ABL. Cell cycle variables were not affected by this compound. These data indicate that blockage of BCR-ABL-induced NF-KB activation via IKB kinase B inhibition represents a potential new approach for treatment of Imatinib-or Dasatinib-resistant forms of chronic myelogenous leukemia. [Mol Cancer Ther 2008;7(2):391 -7] 
Introduction
The t(9;22)(q34;q11) chromosomal translocation is the most frequent cytogenetic abnormality found in human leukemias where it can be detected in f95% of patients with chronic myelogenous leukemia (CML) and in 30% to 40% of pre-B and acute lymphoblastic leukemia (1 -3) . This translocation results in the fusion of the BCR and ABL genes, leading to the expression of a BCR-ABL fusion protein with constitutively active ABL tyrosine kinase activity (1, 4) . BCR-ABL-induced signaling is known to activate Ras-dependent signaling, phosphatidylinositol-3-kinase/Akt, and the Jak/STAT pathway (5) . Additionally, BCR-ABL activates the transcription factor nuclear factor-nB (NF-nB) at least partly in a manner dependent on Ras (6) . Suppression of NF-nB activation by expression of the so-called superrepressor form of InBa blocked BCR-ABL-dependent xenograft tumor formation (6) . Others (7) have also observed that NF-nB is activated by BCR-ABL in manner dependent on Ras. Furthermore, that study reported constitutive NF-nB DNA-binding activity in CML blasts (7) .
The NF-nB/Rel family of transcription factors is comprised of homodimers and heterodimers of p65/RelA, cRel, RelB, NF-nB1/p50, or NF-nB/p52 (8) . NF-nB is negatively regulated by the InB family of inhibitory proteins, which functions to promote cytoplasmic accumulation of NF-nB dimers and to prevent DNA-binding activity (8) . NF-nB is activated downstream of signals elicited by inflammatory cytokines, such as tumor necrosis factor, and by bacterial products, such as lipopolysaccharide (8) . The primary mechanism for activation of NF-nB involves the activation of the InB kinase (IKK), which induces the phosphorylation and ubiquitination of InB. This leads to the degradation of the inhibitory InB proteins and the subsequent accumulation of NF-nB dimers in the nucleus (8) . IKK is composed of two catalytic subunits, IKKa and IKKh, and a regulatory subunit, IKKg/NEMO. IKKh is described as the dominant catalytic subunit in the classic pathway downstream of tumor necrosis factor, and IKKa is involved in a pathway associated with activation of the so-called alternative pathway that activates p52/RelB heterodimers (8) . NF-nB is strongly associated with oncogenesis where it is often important for cell proliferation, suppression of apoptosis, and invasion/metastasis (9, 10) . NF-nB has been shown to be activated in several hematologic malignancies, including CML (see above), acute myelogenous leukemia, acute lymphoblastic leukemia, and Hodgkin's disease (11 -15) . Recently, inhibitors of IKKh have been used to suppress growth of acute myelogenous leukemia cells (16) and a subset of diffuse large B-cell lymphoma (17) .
The hypothesis that CML can be treated by selective inhibition of BCR-ABL has now been shown by the generation of Abl tyrosine kinase inhibitors with positive results in clinical trials of these compounds (18) . Phase 2 studies on the use of Imatinib for the treatment of chronic and advanced-stage CML have shown dramatic responses, with more than 90% of patients with IFNresistant chronic-stage CML achieving a complete hematologic response. Furthermore, f75% of patients with newly diagnosed chronic-phase disease achieve cytogenetic remission (19 -21) . However, most of the patients in blast crisis who initially respond to Imatinib therapy ultimately relapse with disease that is resistant to Imatinib. Resistance to Imatinib in CML patients is caused primarily by point mutations in the kinase domain of BCR-ABL, which impair drug binding (22, 23) . Dasatinib, a second-generation Abl inhibitor, is effective for most Imatinib-resistant CML (24, 25) . However, Dasatinib resistance is generated from mutations occurring directly in the drug binding site on Abl (26) . One of these mutations, T315I, generates resistance to Imatinib, Dasatinib, and Nilotinib (25, 27) . Imatinib resistance can also be generated by poorly described mechanisms. In this regard, IKK inhibition blocked growth of Imatinib-resistant cells (K562 and KCL) that do not express BCR-ABL point mutants (28) . 
Materials and Methods

Cells and Reagents
Ba/F3 cell lines expressing BCR-ABL mutants were developed in the Sawyers laboratory (see ref. 30 ). Ba/F3 and 32D parental cells were maintained in RPMI with 10% fetal bovine serum, 10% conditioned WeHi medium (as a source of interleukin-3), 100 Ag/mL penicillin, and 100 Ag/mL streptomycin (Sigma Chemical). Ba/F3 and 32D cells expressing BCR-ABL oncoproteins (see ref. 6 ; gift of Dr. A.M. Pendergast) were maintained without conditioned WeHi medium. All cell lines were grown at 5% CO 2 at 37jC. Antibodies for c-Abl and cleaved caspase-3 were obtained from Cell Signaling. Antibodies to proliferating cell nuclear antigen and h-tubulin were obtained from Santa Cruz.
Stimulation of Ba/F3 and 32D Cells for Flow Cytometry
To examine apoptosis using flow cytometry, cells were stimulated in the following manner. Cells (0.5 Â 10 6 ) were added to 10 mL growth medium and either DMSO, Imatinib, Dasatinib, the IKKh inhibitor compound A, or compound B (less active), or compound C (an inactive structural analog of compound A) were added for 24 h at concentrations shown in the figures or figure legends. The cells were processed for flow cytometry as described below.
Cell Growth/Viability Cell viability after treatment was measured by spectrophotometric monitoring of MTS reduction using the CytoquantAQ assay system (Promega). After optimization of cell number, an equal number of cells were seeded in a 96-well plate. Inhibitors or DMSO (as indicated in the figures) was added to each well and the cells were incubated at 37jC overnight. CytoquantAQ reagent (20 AL) was added to each well, including the blank wells, and the mixture was incubated for 1 h at 37jC. Absorbance was read at 490 nm.
Apoptosis Assay Apoptosis and cell death were assessed by staining with propidium iodide (PI; BD Biosciences) and APC-labeled Annexin V (BD Biosciences) according to the manufacturer's protocol. After stimulation with the inhibitors described above, the cells were washed twice in ice-cold 1Â PBS. They were then resuspended in 100 AL of 1Â binding buffer (BD Biosciences) and 2.5 AL PI and Annexin V were added to the cells. The cells were incubated at room temperature for 15 min, and 250 AL of 1Â binding buffer was subsequently added to stop the reaction. The cells were analyzed immediately on a Cyan flow cytometer (DakoCytomation). Cell death was characterized by the level of Annexin V and PI staining where apoptotic cells are Annexin V + , PI À and dead cells are Annexin V + , PI + . Cell Cycle Analysis Cell cycle analysis was done by staining with PI (BD Biosciences) according to the manufacturer's protocol. After stimulation for 24 h with the inhibitors described above, 32D and 32D/p185 cells were fixed in ice-cold 70% ethanol (added dropwise while vortexing) for 1 h at 4jC. The cells were then centrifuged (400 Â g for 5 min) and washed once in staining buffer (2% fetal bovine serum, 1Â PBS). After centrifugation, the cells were resuspended in 100 AL staining buffer. The cells were then treated with RNase A (Sigma; 1 AL/sample) and incubated for 30 min at 37jC. After RNase A incubation, the cells were stained for 30 min at room temperature (protected from light) with 10 Ag PI in a final volume of 0.5 mL staining buffer. The samples were then analyzed by flow cytometry at a flow rate <400 events/s. The percentage of cells in G 0 -G 1 , S, and G 2 -M were calculated using ModFit (Verity Software House).
Western Blot Analysis Western blot analysis was done after fractionation of cellular contents into cytosolic and nuclear fractions or whole-cell lysis as indicated. Proteins (20 Ag/lane) from the extracts were separated using NuPAGE Novex 4% to 12% bis-Tris gels (Invitrogen) followed by immunoblotting with antibodies as indicated.
Results and Discussion
IKKB Inhibition Decreases IKBA Phosphorylation Levels in BCR-ABL-Expressing Cells
Ba/F3 cells stably expressing p210 BCR-ABL as well as drug-resistant variants, and 32D cells expressing p185 BCR-ABL, were developed previously (see refs. 6, 30). Immunoblotting confirms the expression of BCR-ABL in the different cell lines (Fig. 1A) . As a measure of NF-nB activation downstream of BCR-ABL, we analyzed phosphorylation of InBa at Ser 32 /Ser 36 . Notably, phosphorylation of InBa is significantly higher in 32D/p185 cells compared with the parental 32D cells (Fig. 1B) , consistent with reports showing that BCR-ABL induces NF-nB activation (6, 7) . Additionally, this result shows that IKK is activated downstream of BCR-ABL because IKK phosphorylates InBa at Ser 32 whereas compound A but not compound C, significantly reduced InBa phosphorylation in 32D/p185 cells (Fig. 1B) , indicating that BCR-ABL activates IKK, which induces InBa phosphorylation. Additionally, these results show that compound A is an effective inhibitor of IKK/NF-nB activation downstream of BCR-ABL-induced signaling.
BCR-ABL Expression Induces Susceptibility to IKKB Inhibition
Previously (6), we have shown that BCR-ABL induces strong NF-nB-dependent transcriptional activity and that inhibition of NF-nB via InBa expression blocked tumor growth driven by BCR-ABL in a xenograft model. Based on these results, we asked whether IKKh inhibitor compound A (1 Amol/L) would affect the growth/viability of 32D cells or 32D/p185 cells as measured in a MTT assay. The effects of IKKh inhibitor compound A were compared with the effects of Imatinib (1 Amol/L) and Dasatinib (5 nmol/L), both with well-established activity against BCR-ABLexpressing cells. Additionally, we included an IKKh inhibitor (compound B) with weaker activity than IKKh inhibitor compound A and an inactive, related compound (compound C). The results (Fig. 2) show that IKKh inhibitor compound A, at a dose of 1 Amol/L, is effective at suppressing cell growth/viability of 32D/p185 cells with minimal effects on the parental 32D cells. As expected, Imatinib and Dasatinib each reduced cell growth/viability of 32D/p185 cells. IKKh inhibitor compound B reduced viability of 32D/p185 cells but less effectively than IKKh inhibitor compound A, consistent with its lower effectiveness as an IKKh inhibitor. The inactive IKKh inhibitor compound did not affect cell growth/viability. Similar results were observed with the pro-B Ba/F3 cell line expressing p210 BCR-ABL (Fig. 2B) , although the IKKh inhibitor reduced cell growth/viability of the parental pro-B cells, presumably indicating the involvement of NF-nB at some level in control of proliferation or survival of these cells. Titration of IKKh inhibitor compound A showed observable cell growth/viability effects around 100 nmol/L, with an f10-folder stronger effect at that concentration, and at 1 and 10 Amol/L, in 32D/p185 cells compared with the 32D parental cells (Fig. 2C) .
WEHI medium does not overcome the inhibitory effect of IKKh blockade on 32D/p185 cell viability. WEHIcontrolled growth/survival does not require IKKh in myeloid cells where BCR-ABL is inactive.
Expression of BCR-ABL generates growth factor -independent growth of 32D myeloid cells (5) . Addition of WEHI medium (as a source of interleukin-3 and granulocyte-macrophage colony-stimulating factor) to BCR-ABL-expressing cells overcomes the inhibitory block on cell viability induced by Imatinib or Dasatinib, essentially recreating a myeloid cell without BCR-ABL activity (Fig. 3A) . However, IKKh inhibitor-treated 32D/p185 cells cannot be rescued with WEHI medium (Fig. 3A) . This result suggests one of the following possibilities: (a) WEHI medium/interleukin-3 requires IKK/NF-nB to promote cell growth/survival, (b) BCR-ABL-activated signaling where IKKh is inhibited interferes with the ability of interleukin-3 to induce cell survival, or (c) NF-nB activity promoted by growth factor support, which involves Stat5 (see ref. 31) , is not sufficient to replace the NF-nB/IKK activity suppressed by IKKh inhibition in the BCR-ABL-expressing cells. This latter hypothesis may be explained by different forms of NF-nB activated by growth factors versus BCR-ABL, by different modifications to NF-nB in response to growth factors or to BCR-ABL expression leading to distinct gene responses, or by a function of IKK controlled by BCR-ABL that is not regulated by growth factors. We then asked if 32D/p185 cells exposed to IKKh inhibitor could be rescued with WEHI medium or with Imatinib and WeHi medium. 32D/p185 cells were incubated in the presence or absence of WEHI and/or Imatinib for 24 h. Subsequently, IKKh inhibitor compound A (or C) was added for an additional 20 h and cell viability was assessed. The results of this experiment (Fig. 3B) reveal that WEHI alone does not rescue the cells when IKK is inhibited, consistent with the results shown in Fig. 3A . However, WEHI medium plus Imatinib rescues cell viability in 32D/p185 cells exposed to IKKh inhibitor. This result shows that growth factorinduced growth/survival of 32D cells (where BCR-ABL is inactivated or not expressed) does not require IKKh activity. Thus, the effect of IKKh inhibition on blocking rescue of growth/survival by exogenous growth factors is mediated through BCR-ABL-controlled suppression of the growth factor response under these conditions and/or through inhibition of an IKK/NF-nB function in BCR-ABL + cells that cannot be recapitulated by growth factors.
IKKB Inhibition Induces Cell Death in BCR-ABLExpressing Cells but Does Not Affect Cell Cycle Variables
To analyze effects on 32D/p185 cell proliferation/ viability induced by IKKh inhibition, cells were treated with Imatinib, Dasatinib, or IKKh inhibitor compound A (or inactive compound C) and were then assessed for cell death by staining with Annexin V and PI. The parental 32D cells exhibited no induction of apoptosis (Annexin V + , PI À ) with the various drug treatments. However, a measurable but relatively modest level early apoptosis was induced in the 32D/p185 BCR-ABL-expressing cells with tyrosine kinase inhibitors or with IKKh inhibitor compound A (Fig. 4A) . These results are consistent with known effects of BCR-ABL on blocking apoptosis in the transformation process (see ref. 32 ). The inactive IKKh inhibitor (compound C) exhibited no effects on apoptosis and showed essentially the same profile as DMSO treatment. Correspondingly, the drug treatments that induced apoptosis also exhibited an increase in late apoptosis/necrosis (Annexin V + , PI + ). To further examine an apoptotic response, immunoblotting was carried out to examine the level of cleaved caspase-3 in these cells following inhibitor treatment. Figure 4B shows that 32D/p185 cells treated with Imatinib, Dasatinib, or IKKh inhibitor exhibit increased levels of cleaved caspase-3 relative to the DMSO control. This result suggests that the increased cell death observed in these cells on drug treatment is mediated at least partly via apoptosis. We note that IKKh inhibition induces less early apoptosis at the 24-h time point compared with BCR-ABL inhibition but relatively equivalent levels of overall cell death (Annexin V + , PI + ). Although there are elevated levels of apoptosis/cell death present in 32D/p185 cells treated with the drugs listed above, it is also possible that these drugs are exhibiting effects via a cell cycle block. Therefore, cell cycle analysis was done. It was observed that 32D/p185 cells exhibit higher levels of G 2 -Mand S-phase compartments compared with parental 32D cells (Fig. 5) . Experiments revealed that treatment with Imatinib or Dasatinib inhibits cell cycle progression in 32D/p185 cells, with enhanced G 0 -G 1 accumulation and reduced numbers in S phase compared with DMSO control. Treatment with IKKh inhibitor compound A, or with inactive compound C, did not significantly alter cell cycle variables. Importantly, it was shown that cell cycle progression is not abrogated in 32D cells treated with these compounds (see Fig. 5 ). Overall, these studies indicate that IKKh inhibition of BCR-ABL-expressing myeloid cells induces a cell death response that can be partly attributed to apoptosis but does not induce a cell cycle block in a specific cell cycle compartment. Future studies will be required to determine if overall cell growth is blocked by IKKh inhibition and whether nonapoptotic forms of cell death contribute to the IKKh inhibition response in BCR-ABL + cells.
IKKB Inhibition Blocks Viability in Cells Expressing
Wild-type, Imatinib-Resistant, or the T315I DasatinibResistant Forms of BCR-ABL Point mutations in the kinase domain of BCR-ABL produce resistance to Imatinib and promote oncogenicity (22 -27) . We analyzed Ba/F3 cells expressing wild-type p210 or variants that are either Imatinib resistant (Y253F and E255V) or both Imatinib and Dasatinib resistant (T315I). Cells were exposed to Imatinib, Dasatinib, IKKh inhibitor (compound A), or the inactive structural variant of the IKKh inhibitor compound (compound C). Consistent with experiments shown above (Fig. 2) , each of the inhibitors strongly reduced the viability of cells expressing wild-type BCR-ABL (Fig. 6 ). As expected, cells expressing mutant variants of BCR-ABL (E255V, Y253H, and T315I) were variably resistant to Imatinib, with the T315I mutant exhibiting complete resistance to Imatinib. Those cells expressing the T315I mutation were also resistant to growth inhibition by Dasatinib (Fig. 6) , as expected. Interestingly, each of the mutant cell lines, including the T315I line, was susceptible to IKKh inhibition. The inactive IKKh inhibitor (compound C) in DMSO showed no inhibitory effects on any of the cells. These studies show that blocking NF-nB/ IKK suppresses viability of cells expressing all forms of BCR-ABL, including wild-type and Imatinib-and Dasatinib-resistant variants, indicating that IKK/NF-nB is required for growth/survival of BCR-ABL + cells.
Summary
The 
